Home / Psoriasis / A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

Brief Summary:

The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm).

This is a three-part study. Participants will enroll in only one part. Parts A and B are for healthy participants and Part C is for participants with psoriasis. Participation could last between 16 and 57 weeks.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: LY3316531 – IV Drug: LY3316531 – SC Drug: Placebo – IV Drug: Placebo – SC Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment :102 participants
Intervention Model:Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title:A Phase 1 Randomized, Placebo-Controlled Study of LY3316531 in Healthy Subjects and an Open-Label, Single-Dose Study in Patients With Psoriasis
Actual Study Start Date :January 30, 2018
Estimated Primary Completion Date :February 2019
Estimated Study Completion Date :September 2019
Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

U.S. FDA Resources


Check Also

Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis

Study Description Go to  Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts …

Leave a Reply

Your email address will not be published. Required fields are marked *